secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-04-23T23:59:59+00:00
Accession:  0000950170-24-046918
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma boosts CEO and CFO retention bonuses to $200K each
-----------------------------------------------------------------

- Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.
- Remaining $165,000 per executive payable on a corporate transaction or clinical development decision approval.
- Amendments effective April 22, 2024; original retention letter terms otherwise unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/0000950170-24-046918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-20240420.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-046918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer